Your request to link to rcsb for MAP%20kinase%20ERK2

• 1ERK: structure of signal-regulated kinase (10.1038/367704A0 )
• 1GOL: coordinates of rat map kinase erk2 with an arginine mutation at position 52 (10.1021/BI952723E )
• 1PME: structure of penta mutant human erk2 map kinase complexed with a specific inhibitor of human p38 map kinase
• 1TVO: the structure of erk2 in complex with a small molecule inhibitor (10.1016/J.BBRC.2005.08.082 )
• 1WZY: crystal structure of human erk2 complexed with a pyrazolopyridazine derivative (10.1016/J.BMCL.2005.09.055 )
• 2ERK: phosphorylated map kinase erk2 (10.1016/S0092-8674(00)80351-7 )
• 2FYS: crystal structure of erk2 complex with kim peptide derived from mkp3 (10.1073/PNAS.0510506103 )
• 2GPH: docking motif interactions in the map kinase erk2 (10.1016/J.STR.2006.04.006 )
• 2OJG: crystal structure of erk2 in complex with n,n-dimethyl-4-(4- phenyl-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide (10.1021/JM061381F )
• 2OJI: crystal structure of erk2 in complex with n-benzyl-4-(4-(3- chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide (10.1021/JM061381F )
• 2OJJ: crystal structure of erk2 in complex with (s)-n-(1-(3-chloro-4- fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1h-pyrazol-3-yl)- 1h-pyrrole-2-carboxamide (10.1021/JM061381F )
• 2Y9Q: crystal structure of human erk2 complexed with a mapk docking peptide (10.1126/SCISIGNAL.2003004 )
• 2Z7L: unphosphorylated mitogen activated protein kinase erk2 in complex with (4-{[5-carbamoyl-4-(3-methylanilino)pyrimidin 2-yl]amino}phenyl)acetic acid (10.1002/PROT.22207 )
• 2ZOQ: structural dissection of human mitogen-activated kinase erk1 (10.1016/J.BBRC.2008.10.127 )
• 3C9W: crystal structure of erk-2 with hypothemycin covalently bound (10.1016/J.JSB.2008.05.002 )
• 3ERK: the complex structure of the map kinase erk2/sb220025 (10.1016/S0969-2126(98)00113-0 )
• 3I5Z: crystal structure of erk2 bound to (s)-n-(2-hydroxy-1-phenylethyl)-4- (5-methyl-2-(phenylamino)pyrimidin-4-yl)-1h-pyrrole-2-carboxamide (10.1021/JM900630Q )
• 3I60: crystal structure of erk2 bound to (s)-4-(2-(2-chlorophenylamino)-5- methylpyrimidin-4-yl)-n-(2-hydroxy-1-phenylethyl)-1h-pyrrole-2- carboxamide (10.1021/JM900630Q )
• 3O71: crystal structure of erk2/dcc peptide complex (10.1016/J.STR.2010.08.011 )
• 3QYW: crystal structure of erk2 in complex with an inhibitor (10.1107/S0907444911023249 )
• 3QYZ: crystal structure of erk2 in complex with an inhibitor (10.1107/S0907444911023249 )
• 3R63: structure of erk2 (spe) mutant (s246e) (10.1128/MCB.05424-11 )
• 3SA0: complex of erk2 with norathyriol (10.1158/0008-5472.CAN-11-2596 )
• 3TEI: crystal structure of human erk2 complexed with a mapk docking peptide (10.1126/SCISIGNAL.2003004 )
• 3W55: the structure of erk2 in complex with fr148083 (10.1016/J.BBRC.2006.12.083 )
• 3ZU7: crystal structure of a designed selected ankyrin repeat protein in complex with the map kinase erk2 (10.1073/PNAS.1205399109 )
• 3ZUV: crystal structure of a designed selected ankyrin repeat protein in complex with the phosphorylated map kinase erk2 (10.1073/PNAS.1205399109 )
• 4ERK: the complex structure of the map kinase erk2/olomoucine (10.1016/S0969-2126(98)00113-0 )
• 4FMQ: crystal structure of human erk2 complexed with a mapk docking peptide (10.1126/SCISIGNAL.2003004 )
• 4FUX: crystal structure of the erk2 complexed with e75
• 4FUY: crystal structure of the erk2 complexed with ek2
• 4FV0: crystal structure of the erk2 complexed with ek3
• 4FV1: crystal structure of the erk2 complexed with ek4
• 4FV2: crystal structure of the erk2 complexed with ek5
• 4FV3: crystal structure of the erk2 complexed with ek6
• 4FV4: crystal structure of the erk2 complexed with ek7
• 4FV5: crystal structure of the erk2 complexed with ek9
• 4FV6: crystal structure of the erk2 complexed with e57
• 4FV7: crystal structure of the erk2 complexed with e94
• 4FV8: crystal structure of the erk2 complexed with e63
• 4FV9: crystal structure of the erk2 complexed with e71
• 4G6N: crystal structure of the erk2
• 4G6O: crystal structure of the erk2
• 4GSB: monoclinic crystal form of the apo-erk2
• 4GT3: atp-bound form of the erk2 kinase
• 4GVA: adp-bound form of the erk2 kinase
• 4H3P: crystal structure of human erk2 complexed with a mapk docking peptide (10.1107/S0907444912051062 )
• 4H3Q: crystal structure of human erk2 complexed with a mapk docking peptide (10.1107/S0907444912051062 )
• 4I5H: crystal structure of a double mutant rat erk2 complexed with a type ii quinazoline inhibitor (10.1016/J.CHEMBIOL.2013.05.005 )
• 4IZ5: structure of the complex between erk2 phosphomimetic mutant and pea-15 (10.1038/NCOMMS2687 )
• 4IZ7: structure of non-phosphorylated erk2 bound to the pea-15 death effector domain (10.1038/NCOMMS2687 )
• 4IZA: structure of dually phosphorylated erk2 bound to the pea-15 death effector domain (10.1038/NCOMMS2687 )
• 4N0S: complex of erk2 with caffeic acid (10.1158/1940-6207.CAPR-14-0141 )
• 4N4S: a double mutant rat erk2 in complex with a pyrazolo[3,4-d]pyrimidine inhibitor (10.1016/J.CHEMBIOL.2014.02.016 )
• 4NIF: heterodimeric structure of erk2 and rsk1 (10.1073/PNAS.1417571112 )
• 4O6E: discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of erk2 (10.1016/J.BMCL.2014.04.068 )
• 4QP1: crystal structure of erk2 in complex with n-cyclohexyl-9h-purin-6- amine (10.1016/J.BMCL.2015.08.048 )
• 4QP2: crystal structure of erks in complex with 5-chlorobenzo[d]oxazol-2- amine (10.1016/J.BMCL.2015.08.048 )
• 4QP3: crystal structure of erk2 in complex with (s)-2-((9h-purin-6-yl) amino)-3-phenylpropan-1-ol (10.1016/J.BMCL.2015.08.048 )
• 4QP4: crystal structure of erk2 in complex with n-cyclohexyl-9h-purin-6- amine (10.1016/J.BMCL.2015.08.048 )
• 4QP6: crystal structure of erk2 in complex with 5h-pyrrolo[2,3-b]pyrazine (10.1016/J.BMCL.2015.08.048 )
• 4QP7: crystal structure of erk2 in complex with 2-(1h-pyrazol-4-yl)-5h- pyrrolo[2,3-b]pyrazine (10.1016/J.BMCL.2015.08.048 )
• 4QP8: crystal structure of erk2 in complex with 2-(1h-pyrazol-4-yl)-7- (pyridin-3-yl)-5h-pyrrolo[2,3-b]pyrazine (10.1016/J.BMCL.2015.08.048 )
• 4QP9: crystal structure of erk2 in complex with 7-(1-propyl-1h-pyrazol-4- yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine (10.1016/J.BMCL.2015.08.048 )
• 4QPA: crystal structure of erk2 in complex with 7-(1-benzyl-1h-pyrazol-4- yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine (10.1016/J.BMCL.2015.08.048 )
• 4QTA: structure of human erk2 in complex with sch772984 revealing a novel inhibitor-induced binding pocket (10.1038/NCHEMBIO.1629 )
• 4QTB: structure of human erk1 in complex with sch772984 revealing a novel inhibitor-induced binding pocket (10.1038/NCHEMBIO.1629 )
• 4QTE: structure of erk2 in complex with vtx-11e, 4-{2-[(2-chloro-4- fluorophenyl)amino]-5-methylpyrimidin-4-yl}-n-[(1s)-1-(3- chlorophenyl)-2-hydroxyethyl]-1h-pyrrole-2-carboxamide (10.1038/NCHEMBIO.1629 )
• 4QYY: discovery of novel, dual mechanism erk inhibitors by affinity selection screening of an inactive kinase state (10.1021/JM500847M )
• 4S2Z: erk2 intrinsically active mutant r65s
• 4S30: erk2 intrinsically active mutant (i84a)
• 4S31: crystal structure of mitogen-activated protein kinase 1 wterk2 at 1.45a
• 4S32: crystal structure of erk2 amp-pnp complex
• 4S33: erk2 r65s mutant complexed with amp-pnp
• 4S34: erk2 (i84a) in complex with amp-pnp
• 4XJ0: crystal structure of erk2 in complex with an inhibitor 14k (10.1021/JM501921K )
• 4XNE: crystal structure of erk2 in complex with an inhibitor (10.1107/S1399004715010342 )
• 4XOY: crystal structure of erk2 in complex with an inhibitor (10.1107/S1399004715010342 )
• 4XOZ: crystal structure of erk2 in complex with an inhibitor (10.1107/S1399004715010342 )
• 4XP0: crystal structure of erk2 in complex with an inhibitor (10.1107/S1399004715010342 )
• 4XP2: crystal structure of erk2 in complex with an inhibitor (10.1107/S1399004715010342 )
• 4XP3: crystal structure of erk2 in complex with an inhibitor (10.1107/S1399004715010342 )
• 4XRJ: crystal structure of erk2 in complex with an inhibitor (10.1107/S1399004715010342 )
• 4XRL: crystal structure at room temperature of erk2 in complex with an inhibitor (10.1107/S1399004715010342 )
• 4ZXT: complex of erk2 with catechol (10.18632/ONCOTARGET.9223 )
• 4ZZM: human erk2 in complex with an irreversible inhibitor (10.1021/ACS.JMEDCHEM.5B00466 )
• 4ZZN: human erk2 in complex with an inhibitor (10.1021/ACS.JMEDCHEM.5B00466 )
• 4ZZO: human erk2 in complex with an irreversible inhibitor (10.1021/ACS.JMEDCHEM.5B00466 )
• 5AX3: crystal structure of erk2 complexed with allosteric and atp- competitive inhibitors. (10.1016/J.BMCL.2015.12.056 )
• 5BUE: erk2 complexed with n-benzylpyridone tetrahydroazaindazole (10.1016/J.BMCL.2015.06.063 )
• 5BUI: erk2 complexed with 2-pyridiyl tetrahydroazaindazole (10.1016/J.BMCL.2015.06.063 )
• 5BUJ: erk2 complexed with a n-h tetrahydroazaindazole (10.1016/J.BMCL.2015.06.063 )
• 5BVD: tetrahydropyrrolo-diazepenones as inhibitors of erk2 kinase (10.1016/J.BMCL.2015.07.091 )
• 5BVE: tetrahydropyrrolo-diazepenones as inhibitors of erk2 kinase (10.1016/J.BMCL.2015.07.091 )
• 5BVF: tetrahydropyrrolo-diazepenones as inhibitors of erk2 kinase (10.1016/J.BMCL.2015.07.091 )
• 5HD4: dissecting therapeutic resistance to erk inhibition rat wild type sch772984 in complex with (3r)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl) phenyl]piperazin-1-yl}ethyl)-n-[3-(pyridin-4-yl)-2h-indazol-5- yl]pyrrolidine-3-carboxamide (10.1158/1535-7163.MCT-15-0172 )
• 5HD7: dissecting therapeutic resistance to erk inhibition rat mutant sch772984 in complex with (3r)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl) phenyl]piperazin-1-yl}ethyl)-n-[3-(pyridin-4-yl)-2h-indazol-5- yl]pyrrolidine-3-carboxamide (10.1158/1535-7163.MCT-15-0172 )
• 5K4I: crystal structure of erk2 in complex with compound 22 (10.1021/ACS.JMEDCHEM.6B00389 )
• 5KE0: discovery of 1-1h-pyrazolo 4,3-c pyridine-6-yl urea inhibitors of extracellular signal regulated kinase erk for the treatment of cancers (10.1021/ACS.JMEDCHEM.6B00708 )
• 5LCJ: in-gel activity-based protein profiling of a clickable covalent erk 1/2 inhibitor (10.1039/C6MB00367B )
• 5LCK: a clickable covalent erk 1/2 inhibitor (10.1039/C6MB00367B )
• 5NGU: human erk2 with an erk1/2 inhibitor (10.1021/ACS.JMEDCHEM.7B00267 )
• 5NHF: human erk2 with an erk1/2 inhibitor (10.1021/ACS.JMEDCHEM.7B00267 )
• 5NHH: human erk2 with an erk1/2 inhibitor (10.1021/ACS.JMEDCHEM.7B00267 )
• 5NHJ: human erk2 with an erk1/2 inhibitor (10.1021/ACS.JMEDCHEM.7B00267 )
• 5NHL: human erk2 with an erk1/2 inhibitor (10.1021/ACS.JMEDCHEM.7B00267 )
• 5NHO: human erk2 with an erk1/2 inhibitor (10.1021/ACS.JMEDCHEM.7B00267 )
• 5NHP: human erk2 with an erk1/2 inhibitor (10.1021/ACS.JMEDCHEM.7B00267 )
• 5NHV: human erk2 with an erk1/2 inhibitor (10.1021/ACS.JMEDCHEM.7B00267 )
• 5U6I: discovery of mli-2, an orally available and selective lrrk2 inhibitor that reduces brain kinase activity (10.1021/ACS.JMEDCHEM.7B00045 )
• 5UMO: structure of extracellular signal-regulated kinase (10.2210/PDB1ERK/PDB )
• 5V60: phospho-erk2 bound to amp-pcp (10.1021/ACSMEDCHEMLETT.7B00127 )
• 5V61: phospho-erk2 bound to bivalent inhibitor sbp2 (10.1021/ACSMEDCHEMLETT.7B00127 )
• 5V62: phospho-erk2 bound to bivalent inhibitor sbp3 (10.1021/ACSMEDCHEMLETT.7B00127 )
• 5WP1: complex of erk2 with 5,7-dihydroxychromone
• 6CPW: discovery of 3(s)-thiomethyl pyrrolidine erk inhibitors for oncology (10.1016/J.BMCL.2018.04.063 )
• 6D5Y: crystal structure of erk2 g169d mutant (10.1158/1078-0432.CCR-17-3674 )
• 6DCG: discovery of mk-8353: an orally bioavailable dual mechanism erk inhibitor for oncology (10.1021/ACSMEDCHEMLETT.8B00220 )
• 6DMG: a multiconformer ligand model of ek6 bound to erk2 (10.1021/ACS.JMEDCHEM.8B01292 )
• 6FI3: crystal structure of erk2 in complex with an adenosine derivative
• 6FI6: crystal structure of erk2 in complex with an adenosine derivative
• 6FJ0: crystal structure of erk2 in complex with an adenosine derivative
• 6FJB: crystal structure of erk2 in complex with an adenosine derivative
• 6FJZ: crystal structure of erk2 in complex with an adenosine derivative
• 6FLE: crystal structure of erk2 in complex with an adenosine derivative
• 6FLV: crystal structure of erk2 in complex with an adenosine derivative
• 6FMA: crystal structure of erk2 in complex with an adenosine derivative
• 6FN5: crystal structure of erk2 in complex with an adenosine derivative
• 6FQ7: crystal structure of erk2 in complex with an adenosine derivative
• 6FR1: crystal structure of erk2 in complex with an adenosine derivative
• 6FRP: crystal structure of erk2 in complex with an adenosine derivative
• 6FXV: crystal structure of erk2 in complex with an adenosine derivative
• 6G54: crystal structure of erk2 covalently bound to sm1-71 (10.1016/J.CHEMBIOL.2019.02.021 )
• 6G8X: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G91: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G92: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G93: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G97: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G9A: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G9D: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G9H: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G9J: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G9K: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G9M: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6G9N: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6GDM: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6GDQ: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6GE0: fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.8B00421 )
• 6GES: crystal structure of erk1 covalently bound to sm1-71 (10.1016/J.CHEMBIOL.2019.02.021 )
• 6GJB: erk2 signalling protein (10.1039/C8SC02754D )
• 6GJD: erk2 signalling protein (10.1039/C8SC02754D )
• 6NBS: wt erk2 with compound 2507-8 (10.1021/ACSCHEMBIO.9B00093 )
• 6OPG: phosphorylated erk2 with amp-pnp (10.1073/PNAS.1906824116 )
• 6OPH: phosphorylated erk2 with gdc-0994 (10.1073/PNAS.1906824116 )
• 6OPI: phosphorylated erk2 with sch-cpd336 (10.1073/PNAS.1906824116 )
• 6OPK: phosphorylated erk2 with vertex-11e (10.1073/PNAS.1906824116 )
• 6OT6: rat erk2 d319n (10.1073/PNAS.1905015116 )
• 6OTS: rat erk2 e320k (10.1073/PNAS.1905015116 )
• 6Q7K: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6Q7S: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6Q7T: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6QA1: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6QA3: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6QA4: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6QAG: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6QAH: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6QAL: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6QAQ: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6QAW: erk2 mini-fragment binding (10.1016/J.DRUDIS.2019.03.009 )
• 6RFO: erk2 map kinase with the activation loop of p38alpha (10.1074/JBC.RA120.013590 )
• 6RFP: erk2 map kinase with mutations at helix-g (10.1074/JBC.RA120.013590 )
• 6RQ4: inhibitor of erk2 (10.1158/1535-7163.MCT-19-0505 )
• 6SLG: human erk2 with erk1/2 inhibitor, azd0364. (10.1021/ACS.JMEDCHEM.9B01295 )
• 7AUV: the structure of erk2 in complex with dual inhibitor astx029 (10.1158/1535-7163.MCT-20-0909 )
• 7E73: crystal structure of human erk2 mutant (y36h)
• 7E75: crystal structure of human erk2 mutant (g37c)
• 7NQQ: discovery of astx029, a clinical candidate which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.1C00905 )
• 7NQW: discovery of astx029, a clinical candidate which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.1C00905 )
• 7NR3: discovery of astx029, a clinical candidate which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.1C00905 )
• 7NR5: discovery of astx029, a clinical candidate which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.1C00905 )
• 7NR8: discovery of astx029, a clinical candidate which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.1C00905 )
• 7NR9: discovery of astx029, a clinical candidate which modulates the phosphorylation and catalytic activity of erk1/2 (10.1021/ACS.JMEDCHEM.1C00905 )
• 7OPM: phosphorylated erk2 in complex with orf45 (10.1038/S41467-022-28109-X )
• 7W5O: crystal structure of erk2 with an allosteric inhibitor (10.1016/J.BBRC.2022.01.035 )